Loading

Journal of Cancer Biology and Research

Is Intraoperative Radiotherapy a Standard Technique for Early Breast Cancer?

Editorial | Open Access | Volume 2 | Issue 1

  • 1. Department of Breast Oncology, Aichi Cancer Center Hospital, Japan
+ Show More - Show Less
Corresponding Authors
Masataka Sawaki, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan, Tel: +81-52-762-6111; FAX: +81-52-764- 2963
Citation

Sawaki M (2014) Is Intraoperative Radiotherapy a Standard Technique for Early Breast Cancer? J Cancer Biol Res 2(1): 1015.

EDITORIAL

Recently, two pivotal papers with Intraoperative radiotherapy (IORT) are published [1,2]. The standard treatment for early breast cancer is breast-conserving therapy (BCT) with whole breast external irradiation therapy (WBI) [3]. Even in highly selected patients, omission of radiotherapy increases the risk of local recurrence [4]. In actuality some women are still encouraged to proceed to mastectomy, because of the lack of access to radiotherapy centers or the long course of treatment of WBI. Then shorter treatment option of irradiation is needed, Partial breast irradiation (PBI) has been tested in clinical trials for selected patients. The rationale for PBI is that local recurrences after BCT with or without WBI arise most in the same quadrant as the primary cancer [5]. The main objective of radiotherapy after BCT is considered to be the destruction of residual cancer cells in the operative field. PBI administered around the tumor bed has been comparable to WBI in selected patients in phase II studies [6-9]. Adequate local control, minimal toxicity, and good cosmetic appearance are shown in studies of PBI [10]. IORT is one of these PBI methods, makes it possible to remove the need to attend a radiotherapy center for 25 fractions for WBI. At present, outside the setting of a clinical trial, use of IORT as well as PBI has not been recommended yet [10,11]. They had been remained investigational until the information of phase III on its long-term efficacy compared with WBI and safety becomes available [12], although more than 1,000 IORT procedures were used in the Milan Institute [13,14].

In the ELIOT trial [1], 1,305 patients aged 48-75 years with early breast cancer, a maximum tumor diameter of up to 2.5 cm were randomly assigned to receive either WBI (50 Gy in 25 fractions followed by a boost of 10 Gy in five fractions using an external electron beam without node irradiation) or IORT with electrons (21 Gy in one fraction to the tumor bed using electrons of 6-9 MeV, prescribed to the 90% isodose). The primary endpoint was occurrence of ipsilateral breast tumor recurrences (IBTR). This is an equivalence trial; the equivalence margin was local recurrence of 7.5% in the IORT group. After a medium follow-up of 5.8 years, 35 patients in the IORT group and 4 patients in the WBI group had had an IBTR (p2cm), lymph node metastasis (involved 4 or more), pathological type (poorly differentiated tumor), and triple-negative subtype. The American Society for Radiation Oncology (ASTRO) Task Force recommendations also suggested relevant inclusion criteria for APBI [15]. Second, Toxicity and cosmetic appearance of IORT compared with WBI could be available; these are very important new information. Significantly fewer skin side-effects in the IORT group were observed; erythema, dryness, hyper-pigmentation, and dryness were more common in WBI group, and only fat necrosis was higher in IORT group. In addition, in patients who had been undergone CT scans, pulmonary fibrosis was more common in WBI group than IORT. IORT makes it possible to minimize several side effects, since skin and the subcutaneous tissue can be spared; and to reduce radiation dose to lung and heart; and to be able to achieve early initiation of radiation and to be given without delaying administration of chemotherapy; and to be able to decrease healthcare cost in some countries and spare time required for outpatient treatment due to one fraction [16].

In the TARGIT-A trial [2], radiotherapy using single-dose targeted intraoperative radiotherapy (TARGIT) was compared with whole-breast fractionated external beam radiotherapy (EBRT) for breast cancer. The authors used a miniature electronbeam-driven X-ray source called Intrabeam®, which emits low energetic X-rays with 50 kV from the point source. This device is inserted intraopetatively into the tumor cavity after excision of the tumor and emits X-rays from within the breast [17]. This study was a multi-center, randomized, non-inferiority trial. 3,451 patients aged 45 years and older with invasive ductal carcinoma were enrolled and randomly assigned to receive TARGIT or whole breast EBRT (WBI). 15.2% (239 of 1,571) of patients in the TARGIT group received supplemental EBRT, if unforeseen adverse features were detected on final pathology, which was called a risk-adapted approach. The primary outcome was absolute difference in local recurrence in the conserved breast, with a prespecified non-inferiority margin of 2.5% at 5 years. After a median follow-up of 2 years and 5 months, the 5-year risk for local recurrence in the conserved breast was 3.3% (95% CI: 2.1-5.1) for TARGIT versus 1.3% (0.7-2.5) for EBRT (p=0.042). TARGIT concurrently with lumpectomy (pre-pathology, n=2,298) had much the same results as EBRT: 2.1% (1.1-4.2) versus 1.1% (0.5-2.5; p=0.31). With delayed TARGIT (post-pathology, n=1,153) the between-group difference was larger than 2.5% (TARGIT 5.4% [3.0-9.7] vs EBRT 1.7% [0.6-4·9]; p=0.069). Overall mortality was 3.9% for TARGIT versus 5.3% for EBRT (p=0.099), but there were significantly fewer non-breast-cancer deaths with TARGIT (1.4% [0.8-2.5] vs 3.5% [2.3-5.2]; p=0.0086), attributable to fewer deaths from cardiovascular causes and other cancers. As for adverse events, grade 3 or 4 skin complications were significantly reduced with TARGIT (4 of 1,720 vs 13 of 1,731, p=0.029). As a conclusion, TARGIT concurrent with lumpectomy within a risk-adapted approach should be considered as an option for eligible patients with breast cancer carefully selected patients, as an alternative to postoperative EBRT. In this paper, two important issues are pointed out. First, delayed TARGIT (post-pathology, n=1,153) group had worse recurrence rate. When should be delivered TARGIT; initial lumpectomy with less pathological information, or re-operation after final pathological diagnosis? The answer from the study is with initial lumpectomy, not with delayed procedure. The reason why this difference was caused is not clear, although we need to consider. The main advantages of immediate placement of the radiotherapy are follows: 1) to be able to deliver the radiation before tumor cells have a chance to proliferate under surgical intervention have a rich vascularization, which makes them more sensitive to the action of the radiation; 2) to be able to deliver under direct visualization at the time of surgery, it has the potential capability for accurate dose delivery to the surgical bed directly [16]. These may be one of possible reasons. One area of concern in the use of IORT is the management of positive surgical margins as positivity is discovered at the final histology, a few days after surgery and IORT. The answer with this point was given by the trial. Then, in the trial it is emphasized that this trial is a risk-adapted design, if subsequent pathology suggested adverse histological features then mandatory to complete treatment to the whole breast, although only 15% of cases occurred. TARGIT is an only trial to permit addition of EBRT if the adverse pathological factors are present. Second, there were significantly fewer non-breastcancer deaths with TARGIT group. Cardiovascular causes (cardiac disease; 8, stroke; 2, ischemic bowel; 1) were more seen in EBRT group than TARGIT group. Radiotherapy-induced cardio toxicity has been known within the first 4 years [18]. In this trial it might be possible to reduce radiation dose to lung and heart as well as ELIOT trial, although continuous monitoring is mandatory.

In these pivotal studies, most important issue is patient selection. Anatomical factors; i. e. , tumor size (>2cm), lymph node metastasis (involved 4 or more), and pathological types are very important, and addition, biological subtype features are mandatory to consider indication. Patient’s age less than 45 are not included in these trials, so they should not be indicated. Pathological information is needed to perform appropriate approach, but second procedure after reopening the wound after pathological diagnosis is not recommended because of its higher recurrence rate. As for adverse events, these new methods are less toxic than WBI, mainly skin-side effects, and also cardio toxicity or pulmonary fibrosis, although a longer follow up time is needed for evaluation of late toxicity. Late cosmetic outcome is important for evaluation of radiotherapy, the majority of patients with early breast cancer treated with BCT have acceptable cosmetic outcomes [19], although there is few data evaluating for late changes of cosmesis after IORT.

These new data from ELIOT and TARGIT-A trial, IORT is an alternative to WBI for selected patients at low risk of local recurrence.

REFERENCES

1. Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. 2013; 14: 1269-1277.

2. Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, et al. Risk-adapted targeted intraoperative radiotherapy versus wholebreast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. The Lancet 2013; S0140-6736: 61950-61959.

3. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 366: 2087-2106.

4. Fyles AW, McCready DR, Manchul LA, Trudeau ME, Merante P, Pintilie M, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004; 351: 963-970.

5. Veronesi U, Marubini E, Mariani L, Galimberti V, Luini A, Veronesi P, et al. Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol. 2001; 12: 997-1003.

6. Vicini FA, Kestin L, Chen P, Benitez P, Goldstein NS, Martinez A. Limited-field radiation therapy in the management of early-stage breast cancer. J Natl Cancer Inst. 2003; 95: 1205-1210.

7. Benitez PR, Keisch ME, Vicini F, Stolier A, Scroggins T, Walker A, et al. Five-year results: the initial clinical trial of MammoSite balloon brachytherapy for partial breast irradiation in early-stage breast cancer. Am J Surg. 2007; 194: 456-462.

8. Vicini FA, Baglan KL, Kestin LL, Mitchell C, Chen PY, Frazier RC, et al. Accelerated treatment of breast cancer. J Clin Oncol. 2001; 19: 1993- 2001.

9. Antonucci JV, Wallace M, Goldstein NS, Kestin L, Chen P, Benitez P, et al. Differences in Patterns of Failure in Patients Treated With Accelerated Partial Breast Irradiation Versus Whole-Breast Irradiation: A Matched-Pair Analysis With 10-Year Follow-Up. Int J Radiat Oncol Biol Phys. 2009; 74: 447-452.

10. Njeh CF, Saunders MW, Langton CM. Accelerated Partial Breast Irradiation (APBI): A review of available techniques. Radiat Oncol. 2010; 5: 90.

11. Skandarajah AR, Lynch AC, Mackay JR, Ngan S, Heriot AG. The role of intraoperative radiotherapy in solid tumors. Ann Surg Oncol. 2009; 16: 735-744.

12. Buchholz TA. Radiation therapy for early-stage breast cancer after breast-conserving surgery. N Engl J Med. 2009; 360: 63-70.

13. Intra M, Luini A, Gatti G, Ciocca M, Gentilini OD, Viana AA, et al. Surgical technique of intraoperative radiation therapy with electrons (ELIOT) in breast cancer: a lesson learned by over 1000 procedures. Surgery. 2006; 140: 467-471.

14. Veronesi U, Orecchia R, Luini A, Galimberti V, Zurrida S, Intra M, et al. Intraoperative radiotherapy during breast conserving surgery: a study on 1,822 cases treated with electrons. Breast Cancer Res Treat. 2010; 124: 141-151.

15. Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, Hardenbergh PH, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009; 74: 987-1001.

16. Sawaki M, Kondo N, Horio A, Ushio A, Gondo N, Adachi E, et al. Feasibility of intraoperative radiation therapy for early breast cancer in Japan: a single-center pilot study and literature review. Breast Cancer. 2012; .

17. Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet. 2010; 376: 91-102.

18. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013; 368: 987-998.

19. Olivotto IA, Rose MA, Osteen RT, Love S, Cady B, Silver B, et al. Late cosmetic outcome after conservative surgery and radiotherapy: analysis of causes of cosmetic failure. Int J Radiat Oncol Biol Phys. 1989; 17: 747-753

Sawaki M (2014) Is Intraoperative Radiotherapy a Standard Technique for Early Breast Cancer? J Cancer Biol Res 2(1): 1015.

Received : 26 Dec 2013
Accepted : 15 Jan 2014
Published : 19 Jan 2014
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X